Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
Image File
Original HTML

Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

HONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong Limited (the "HK Stock Exchange"), have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect (collectively, the "Hong Kong Stock Connect") programs, both with effect from September 7, 2026, pursuant to the announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, recently. Following the inclusion of the Shares, eligible investors in Chinese Mainland will be able to trade the Shares through the Hong Kong Stock Connect channel.

The Company believes the inclusion of the Shares in the trading mechanism of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect demonstrates market recognition of the Company's investment value and growth prospects. The Company expects the inclusion of the Shares as eligible securities will help further expand the shareholder base of the Company, increase the trading liquidity of the Shares, and support the innovation-driven and sustainable growth of the Company in the long term.

About the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are mutual stock market access mechanisms between Chinese Mainland and the Hong Kong Special Administrative Region, under which the Shanghai Stock Exchange and the Shenzhen Stock Exchange have established technical connectivity with the HK Stock Exchange, respectively, to enable investors in Chinese Mainland and the Hong Kong Special Administrative Region to trade eligible securities listed on each other's market through their local securities companies or brokers.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once monthly subcutaneously and once daily orally, and ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo

ICR Healthcare

443-231-0505 (U.S.)

[email protected]

Ascletis Pharma Inc. PR and IR Teams

+86-181-0650-9129 (China)

[email protected]

[email protected]

SOURCE Ascletis Pharma Inc.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302870977
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): Final paragraph is generic company boilerplate copied from the source's 'About Ascletis Pharma Inc.' section, adding no news context.
Source Name
Unknown Company
Original Summary

<p>HONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong Limited (the "HK Stock Exchange"), have been included in the list of eligible securities...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS1810014/Ascletis-Pharma-Logo.jpg?id=OA2932180&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Ascletis Shares Added to Hong Kong-China Stock Connect Programs", "body_html": "<p><strong>Hong Kong -- [CURRENT_DATE] --</strong> Ascletis Pharma Inc. (HKEX: 1672) shares have been added to the eligible securities list under both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective September 7, 2026.</p><h5>Mainland Chinese investors gain direct access to Ascletis shares via Stock Connect channels</h5><p>The inclusion follows announcements from the Shanghai Stock Exchange and the Shenzhen Stock Exchange. Eligible investors in Chinese Mainland can now trade Ascletis ordinary shares through the Hong Kong Stock Connect mechanism, which links the Shanghai and Shenzhen exchanges with the Hong Kong Stock Exchange for cross-border trading via local brokers.</p><h5>Company expects wider shareholder base and improved trading liquidity</h5><p>Ascletis said the listing reflects market recognition of its investment value and growth prospects. The company anticipates the eligible-securities status will expand its shareholder base, increase trading liquidity of its shares, and support long-term innovation-driven growth.</p><h5>Ascletis develops oral and injectable metabolic disease candidates including GLP-1R agonist ASC30</h5><p>Ascletis is a biotechnology company focused on metabolic disease therapeutics, using its AI-assisted Structure-Based Drug Discovery, Ultra-Long-Acting Platform, and Peptide Oral Transport ENhancement Technology platforms. Its pipeline includes ASC30, a once-daily oral GLP-1R agonist for chronic weight management and diabetes, alongside multiple fixed-dose combination candidates such as ASC30_48FDC and ASC30_48_39FDC targeting GLP-1R, GIPR and amylin receptor pathways.</p>", "meta_description": "Ascletis Pharma shares join Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening mainland Chinese investor access from September 7, 2026.", "seo_keywords": "Ascletis Pharma, Hong Kong Stock Connect, HKEX 1672, Shanghai Stock Exchange, Shenzhen Stock Exchange, biotech listing, metabolic disease drugs, GLP-1R agonist", "companies": ["Ascletis Pharma Inc."], "industries": ["Biopharmaceuticals"], "markets_regions": ["China", "APAC"], "news_type": ["regulatory_update", "financial_disclosure"], "products": ["ASC30"], "themes": ["capital_markets", "regulatory_compliance"], "events": [], "cta_text": "Details on Ascletis' Stock Connect eligibility and pipeline are available via company disclosures.", "learn_more": "http://www.ascletis.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}